MedPath

FDA Approves Biogen's Qalsody, First Treatment Targeting Genetic Cause of ALS

  • The FDA has approved Qalsody (tofersen) from Biogen, the first treatment targeting a genetic cause of amyotrophic lateral sclerosis (ALS).
  • Qalsody is indicated for adults with ALS who have a mutation in the superoxide dismutase 1 (SOD1) gene, representing about 2% of ALS cases.
  • The approval was based on the reduction in plasma neurofilament light chain, a marker of neurodegeneration, observed in patients treated with Qalsody.
  • This approval marks a pivotal moment in ALS research, establishing neurofilament as a surrogate marker reasonably likely to predict clinical benefit in SOD1-ALS.
Biogen's Qalsody (tofersen) has received FDA approval as the first treatment to target a genetic cause of amyotrophic lateral sclerosis (ALS). The approval, granted on Tuesday, targets a specific and devastating ultra-rare genetic form of the progressive neurodegenerative disease.
Qalsody is indicated for the treatment of ALS in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene. This approval marks a significant advancement, offering a therapy that addresses the underlying genetic cause of SOD1-ALS, which affects approximately 2% of all ALS cases, or about 330 people in the U.S.

Mechanism of Action and Clinical Evidence

The FDA's decision was primarily based on the observed reduction in plasma neurofilament light chain levels in patients treated with Qalsody. Neurofilaments are proteins released from neurons upon damage, serving as a marker for neurodegeneration. The clinical trial data demonstrated that Qalsody effectively lowered these neurofilament levels, suggesting a potential slowing of disease progression.
Christopher Viehbacher, Biogen’s president and CEO, emphasized the importance of this milestone, stating, "Today also marks a pivotal moment in ALS research as we gained, for the first time, consensus that neurofilament can be used as a surrogate marker reasonably likely to predict clinical benefit in SOD1-ALS. We believe this important scientific advancement will further accelerate innovative drug development for ALS."

Administration and Target Population

Qalsody is administered via spinal injection by healthcare professionals experienced in performing lumbar punctures. SOD1-ALS is a progressive neurodegenerative disease characterized by the degeneration of nerve cells controlling voluntary muscles, leading to muscle weakness and paralysis. The therapy aims to mitigate the effects of the SOD1 mutation, which causes the production of a toxic protein that damages motor neurons.

Community Impact

Jean Swidler, chair of Genetic ALS & FTD: End the Legacy, highlighted the significance of this approval for families affected by SOD1-ALS, noting, "Qalsody offers families who have lost generation after generation in the prime of their life to this devastating disease a therapy targeting the underlying cause of SOD1-ALS."

Broader Context of ALS Treatment

This approval follows the FDA's recent approval of Amylyx Pharmaceuticals' Relyvrio, another ALS treatment, underscoring the increasing momentum in developing therapies for this challenging disease. With an estimated 30,000 people in the U.S. living with ALS, the development of new treatments offers hope for improved outcomes and quality of life.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Tofersen Receives Green Light in Japan for SOD1-Related ALS

Japan's health ministry panel has approved tofersen, a drug developed by Biogen, for treating amyotrophic lateral sclerosis (ALS) patients with SOD1 gene mutations.

Ractigen's RAG-21 Receives FDA Orphan Drug Designation for FUS-ALS Treatment

Ractigen Therapeutics' RAG-21, a novel siRNA therapy targeting the FUS gene, has received FDA Orphan Drug Designation for amyotrophic lateral sclerosis (ALS).

FDA Grants Orphan Drug Designation to Ractigen's RAG-21 for FUS-ALS

The FDA has granted Orphan Drug Designation to Ractigen Therapeutics' RAG-21 for amyotrophic lateral sclerosis (ALS) treatment, specifically targeting the FUS subtype.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq) for treating Aromatic L-Amino Acid Decarboxylase (AADC) deficiency in adults and children.

FDA Approves Kebilidi, First Gene Therapy for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi, a gene therapy for treating aromatic L-amino acid decarboxylase (AADC) deficiency, a rare and severe genetic disorder.

Trace Neuroscience Launches with $101M to Tackle ALS Using Antisense Technology

Trace Neuroscience launched with $101 million in funding to develop genetic medicines for amyotrophic lateral sclerosis (ALS), a neurodegenerative disease with limited treatment options.

FDA Approves Kebilidi, First Brain-Delivered Gene Therapy for AADC Deficiency

The FDA has approved Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for AADC deficiency, marking the first brain-delivered gene therapy approved in the U.S.

FDA Approves PTC Therapeutics' Kebilidi, First Gene Therapy Dosed Directly into the Brain

The FDA has approved Kebilidi (eladocagene exuparvovec), a gene therapy by PTC Therapeutics, for aromatic L-amino acid decarboxylase (AADC) deficiency, a rare genetic disorder.

FDA Approves Kebilidi, First Gene Therapy Directly Administered to the Brain for AADC Deficiency

The FDA has granted accelerated approval to Kebilidi (eladocagene exuparvovec-tneq), a gene therapy for both children and adults with AADC deficiency, a rare genetic disorder.

DR.NOAH Biotech's AI-Driven ALS Drug, NDC-011, Receives FDA Approval for Phase 1 Trial

DR.NOAH Biotech received FDA approval for its Investigational New Drug (IND) application for Phase 1 clinical trial of NDC-011, a new drug combination for Amyotrophic Lateral Sclerosis (ALS).

Reference News

[1]
Biogen receives FDA approval for breakthrough ALS treatment: ‘Pivotal moment in ALS research’
thegardenisland.com · Apr 25, 2023

Biogen's Qalsody, targeting SOD1-ALS, a rare genetic form of ALS, received FDA approval. It's the first treatment addres...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy